Lebrikizumab Demonstrates Consistent Efficacy at 16 Weeks in Patients With Moderate-to-Severe Atopic Dermatitis Regardless of Baseline Disease Severity

Main Article Content

Linda Stein Gold
Henry Ford Health System, Detroit, USA

Kilian Eyerich
Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden and University of Freiburg, Freiburg, Germany

Howard Sofen
David Geffen School of Medicine, University of California Los Angeles, Los Angeles, USA

Pedro Herranz
Hospital Universitario La Paz, Madrid, Spain

Leon Kircik
Icahn School of Medicine at Mount Sinai, New York, USA

Tony Bewley
Royal London Hospital, London, UK

Eric Wolf
Eli Lilly and Company, Indianapolis, USA

Gaia Gallo
Eli Lilly and Company, Indianapolis, USA

Yuxin Ding
Eli Lilly and Company, Indianapolis, USA

Fan Emily Yang
Eli Lilly and Company, Indianapolis, USA

Ignasi Pau-Charles
Almirall, S.A., Barcelona, Spain

Melinda Gooderham
Queen's University and Probity Medical Research, Peterborough, Canada

Keywords

Lebrikizumab, efficacy, atopic dermatitis

References

1. Okragly AJ, et al. Dermatol Ther (Heidelb). 2023;13:1535-1547.

2. Silverberg JI, et al. N Engl J Med. 2023;388:1080-1091.

3. Blauvelt A, et al. Br J Dermatol. 2023;188:740-748.

4. Yosipovitch G, et al. Br J Dermatol. 2022;186:e145.

Article Sidebar

PDF
Published
Nov 13, 2023
DOI https://doi.org/10.25251/skin.7.supp.274

Article Details

How to Cite
Stein Gold, L. ., Eyerich, K. ., Sofen, H. ., Herranz, P. ., Kircik, L. ., Bewley, T. ., Wolf, E. ., Gallo, G. ., Ding, Y. ., Yang, F. E. ., Pau-Charles, I. ., & Gooderham, M. . (2023). Lebrikizumab Demonstrates Consistent Efficacy at 16 Weeks in Patients With Moderate-to-Severe Atopic Dermatitis Regardless of Baseline Disease Severity. SKIN The Journal of Cutaneous Medicine, 7(6), s274. https://doi.org/10.25251/skin.7.supp.274
Issue
Vol. 7 No. 6 (2023): November 2023 Issue
Section
Atopic Dermatitis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>